Objective To investigate levels of 8-isoprostane in serum of patients with bronchial asthma. Methods Eighteen patients diagnosed with acute exacerbation of asthma were enrolled as the experimental group from Department of Respiratory Medicine from February 2009 to August 2009. After treatment all the patients reached remission. Twenty healthy workers from Department of Respiratory Medicine were enrolled as the control group in August 2009. The levels of 8-isoprostane in serum of all subjects were measured, and their FEV1% pred was also evaluated. Results The levels of 8-isoprostane in serum were significantly higher in patients with acute exacerbation of asthma compared with those in remission stage and the healthy control group [ ( 157. 46 ±46. 99) pg/mL vs. ( 43. 52 ±13. 62) pg/mL and( 15. 23 ±1. 96) pg/mL, P lt;0. 01] . Meanwhile the levels of 8-isoprostane in serum of patients with asthma in remission stage were significantly higher compared with the healthy control group ( P lt;0. 05) . The levels of 8-isoprostane in serum were negatively correlated with FEV1% pred in the asthma group( r = - 0. 533,P lt;0. 05) . Conclusions 8-isoprostane as amarker of oxidative stress response involves in the pathogenesis of asthma. Monitoring 8-isoprostane levels in serum may reflect the state of oxidative stress, and may be useful for severity judgment and follow-up of treatment effectiveness in patients with asthma.
Objective To invesitgate the relationship between 8-isoprostane ( 8-iso-PG) level in exhaled breath condensates ( EBCs) and severity of asthma and explore the role of 8-iso-PG in asthma evaluation and monitoring. Methods Fifty-nine patients with asthma were enrolled. In which 15 cases were acute exacerbation, 13 cases were mild intermittent, 15 cases were mild persistent, and 16 cases were moderate-to-severe persistent. Thirteen healthy volunteers were recruited as control. EBCs were collected using EcoScreen system. The 8-iso-PG levels in EBCs were measured by a specific enzyme immunoassay.The patients with mild intermittent asthma were treated with inhaled corticosteroid ( ICS) for one month and their EBCs were recollected for 8-iso-PG measurement. Results Exhaled 8-iso-PG levels were obviously increased in the patients with acute asthma compared with those chronic asthmatics [ ( 47. 2 ±6. 8) pg/mL vs ( 24. 5 ±12. 0) pg/mL, P lt; 0. 01] . In the chronic persistent asthma, the levels were significantly higher in patients with mild persistent and moderate-to-severe asthma [ ( 17. 9 ±1. 2) pg/mL and ( 39. 7 ±4. 0) pg/mL,P lt; 0. 01] . While 8-iso-PG level did not differ significantly in intermittent asthma [ ( 13. 5 ±1. 1) pg/mL]compared with the control subjects ( P gt; 0. 05 ) . After one-month ICS treatment the 8-iso-PG level in the patients with mild intermittent asthma did not change significantly although the ACT score improved. Conclusions 8-iso-PG levels in EBC are associated with the severity of asthma, implicating 8-iso-PG may be useful in monitoring airway oxidative stress in asthma. ICS treatment is incapable of decreasing the 8-iso-PG, suggesting the ICS has minor impact on oxidative stress.